Previous 10 | Next 10 |
Today, we check back in on a developmental firm called Cerecor that is focused on developing treatments for rare pediatric and orphan diseases. This is the first revisit in the last 11 months. The company seems to be advancing its pipeline and recently did a capital raise to address f...
ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has grant...
Are These 5 Cheap Biotech Penny Stocks Worth It? With only a week or so left in January, penny stocks remain a hot item in the market. As an investor, it’s important to monitor certain trends. Right now could the time to find some biotech penny stocks to watch. Many of th...
Cerecor ([[CERC]] -1.0%) announces exercise by the underwriters of their option to purchase an additional 1,648,812 shares at a price to the public of $2.60/share.This increases the total offered through the previously announced underwritten public offering to 13,971,819 of common stock and 1...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today t...
Armistice Capital, holder of 10% shares of Cerecor (CERC) adds 2.5M common shares to its existing holding for the total transaction value of $6.5M.Post share acquisition, Capital direct holding is 32.6M.Shares +6% in premarket.Press ReleasePreviously (Jan. 8): Cerecor prices $36.4M ...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the closing of the previou...
Sarepta Therapeutics (SRPT) -48% as DMD gene therapy treatment fails to meet primary endpoint.Neoleukin Therapeutics (NLTX) -19% after receiving clinical hold letter from FDA related to CMC assay development for NL-201.Solid Biosciences (SLDB) -18% after Sarepta ...
Cerecor (CERC) inks agreement with Jefferies under which the underwriters have agreed to purchase, on a firm commitment basis, ~12.3M common shares at $2.60/share.In addition, the Company is offering pre-funded warrants to purchase up to ~1.7M common shares at $2.599/warrant.Expected gross pr...
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into a...
News, Short Squeeze, Breakout and More Instantly...
Cerecor Inc. Company Name:
CERC Stock Symbol:
NASDAQ Market:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at...